Clinical Policy: Zoledronic Acid (Reclast)
Defines medical necessity and prior authorization criteria for zoledronic acid (Reclast/Zometa) for osteoporosis, Paget disease, hypercalcemia of malignancy, multiple myeloma, bone metastases, and select off-label oncologic/other uses for members covered by mhn.
For initial approval revised approval duration for Medicaid/HIM from 6 to 12 months for multiple myeloma, solid tumor, systemic mastocytosis, and histiocytic neoplasms.
Added step therapy bypass for Illinois Health Information Model per IL HB 5395.
For osteoporosis, clarified failure of 'generic' alendronate is preferred.
Removed distinction between branded Zometa and Reclast as Zometa became obsolete; removed prior requirement preventing combined use.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.